Industry Braces for FDA User Fee Riders As Democrats Take Congress

Inside Health Policy quotes former FDA officials, NCHR Diana Zuckerman, industry groups, and US Pharmacopeia on likely user fee (PDUFA) legislation riders.

By James Jarvis / November 9, 2026 


As drug industry stakeholders assess what a Democratic-controlled Congress could mean for their legislative priorities, several expect the new majority to use next year’s FDA user fee reauthorizations to pursue additional oversight of agency staffing and spending, and potentially advance measures aimed at increasing generic and biosimilar competition as part of the party’s broader push to lower prescription drug prices. 

With FDA expected to send the proposed PDUFA VIII, GDUFA IV, BsUFA IV and other medical product user fee agreements to Congress in January, lawmakers will have until September 2027 to reauthorize the programs, providing Democrats with a major legislative opportunity to pursue FDA policy priorities that have struggled to gain traction in recent years. 

[….]

Sen. Bernie Sanders (I-VT) is set to become chair of the Senate health committee and could also push for riders focused on drug pricing or reforms to the user fee process. Sanders has in the past voted against user fee bills due to concerns that industry funding for FDA’s work creates conflicts of interest at the agency. 

“I think it’s highly unlikely that it’s a clean user fee [reauthorization],” Julie Tierney, a principal at Leavitt Partners and former FDA official who has worked through several reauthorization cycles, told Inside Health Policy. Tierney said, “Based on the conversations I’ve had, as well as public statements that have been made over the past 48 hours… I would expect there to be some emphasis on transparency and perhaps more reporting [requirements]… and other things like that.” 

[….]

FDA Staffing, Spending Transparency Could Draw Scrutiny 

Tierney said she expects Democrats to place particular emphasis on FDA staffing and how the agency has spent industry-paid user fees following the Trump administration’s workforce reductions and subsequent restructuring.  

[….]

Tierney said Democrats could seek more detailed staffing reports, along with safeguards intended to ensure the agency’s policies and scientific decisions remain insulated from political pressure. 

Beyond staffing, Tierney also pointed to questions about how FDA is allocating industry-paid fees as administrative functions are consolidated under the agency’s expanded shared-services model. 

Although PDUFA VIII includes additional financial reporting requirements, Tierney said stakeholders may want more detailed information about how user-fee funding is being used within FDA’s Office of Operations and whether those expenditures are supporting the review programs for which the fees were collected. 

Congressional Democrats have already raised questions about FDA’s handling of user fee funds following the workforce reductions.

 In July, House Energy & Commerce Committee ranking Democrat Frank Pallone (NJ) sent a letter to the Government Accountability Office asking investigators to examine whether FDA unlawfully used industry-paid user fees to cover severance and other costs stemming from the Trump administration’s 2025 workforce cuts. 

Association for Accessible Medicines (AAM) President and CEO John Murphy, whose group served as the lead industry negotiator for GDUFA IV and BsUFA IV, acknowledged that the administration’s workforce reductions diminished some of FDA’s capabilities but said the agreements represent meaningful progress in addressing staffing and review concerns. 

[….]

“The most important thing for us is to make sure that we have that pathway to get the user fees reauthorized,” Murphy said. 

Gil Roth, president of the Pharma & Biopharma Outsourcing Association (PBOA), similarly emphasized the importance of preserving the negotiated commitments while acknowledging that Congress is likely to bring additional FDA priorities to the table. 

[….]

Drug Safety, Competition Reforms Could Also Be In Play 

Beyond staffing and spending transparency, Diana Zuckerman, president of the National Center for Health Research, said she hopes Democrats will pursue additional measures addressing FDA’s drug review and postmarket oversight practices, which she argues were largely left out of the proposed PDUFA VIII and GDUFA IV agreements. Zuckerman said the agreements place too much emphasis on accelerating application reviews and providing additional opportunities for manufacturers to engage with FDA without adequately addressing concerns about the quality of those reviews or the agency’s oversight of medicines after approval. 

She pointed specifically to FDA’s handling of manufacturing and drug-quality problems involving generic medicines, arguing that the agency has not always adequately informed the public when it identifies potentially serious issues. 

“There’s a lot of concerns about generic drugs staying on the market even after FDA had found that there was contamination or dosage problems in the way the products were being made, and hundreds of generic drugs that the FDA acknowledged were problematic, and … they couldn’t trust the data, but they didn’t notify the public,” Zuckerman told Inside Health Policy. 

Similar concerns surfaced during FDA’s September public meeting on GDUFA IV, when consumer advocates criticized the proposal for focusing heavily on application reviews while doing relatively little to address post-market testing, inspections and public disclosure of drug-quality problems. 

Zuckerman also said she expects Democrats to scrutinize whether FDA has sufficient resources to conduct foreign inspections, particularly at manufacturing facilities in India and China, which have attracted increased attention from lawmakers in both parties and the administration. 

Meanwhile, some industry representatives anticipate lawmakers could use the reauthorization bills to pursue additional measures aimed at increasing generic and biosimilar competition, potentially creating an opportunity for Democrats to advance parts of their broader drug-affordability agenda. 

During a legislative outlook panel at AAM’s Generics and Biosimilars Conference Monday (Nov. 2), industry representatives outlined several potential additions to the user-fee legislation that were not addressed in the negotiated agreements, including changes to Risk Evaluation and Mitigation Strategies (REMS) requirements, greater clarity around generic and biosimilar exclusivity determinations and measures aimed at reducing inspection-related approval delays. 

[….]

 Murphy, however, suggested Congress should also look beyond FDA’s review process and examine financial incentives and other market practices that can prevent patients from accessing generics and biosimilars even after the agency approves them. “We are seeing approvals. What we are not seeing is access,” 

Murphy said, pointing to pharmacy benefit manager and brand-manufacturer practices that he argues continue to discourage greater adoption of lower-cost alternatives. Murphy said AAM intends to raise those concerns as it engages with incoming lawmakers, although broader reimbursement and drug-pricing changes may need to be pursued separately from the FDA legislation.

But Kimberly Trzeciak, vice president of U.S. government and regulatory affairs at U.S. Pharmacopeia, cautioned during the AAM panel that a change in congressional control could complicate the already tight user fee reauthorization timeline, particularly as incoming Democratic committee leaders pursue additional FDA oversight. 

“While the agreements do have to be up there by January 15th … I think there’s going to be a lot of pent-up interest in oversight, which could delay the typical hearing process,” Trzeciak said. 

[….]

Democrats’ Large Senate Majority Could Ease Reauthorization 

Despite expectations that lawmakers will pursue additional policy provisions, some experts believe Democrats’ larger-than-expected Senate majority could make passage of the user fee legislation less difficult than initially anticipated. 

Elizabeth Jungman, a partner at Hogan Lovells Calwalader, said one concern before the election was that an extremely narrow majority could give individual senators significant leverage to demand specific FDA policy concessions in exchange for supporting the broader package. 

But Democrats’ larger majority reduces that risk by giving congressional leaders more flexibility to negotiate legislation without relying on every member of their caucus, she said. 

[….]

To read the entire article, click here Industry Braces For FDA User Fee Riders As Democrats Take Congress | InsideHealthPolicy.com